Literature DB >> 9621034

Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles.

S C Chen1, D H Jones, E F Fynan, G H Farrar, J C Clegg, H B Greenberg, J E Herrmann.   

Abstract

DNA vaccines are usually given by intramuscular injection or by gene gun delivery of DNA-coated particles into the epidermis. Induction of mucosal immunity by targeting DNA vaccines to mucosal surfaces may offer advantages, and an oral vaccine could be effective for controlling infections of the gut mucosa. In a murine model, we obtained protective immune responses after oral immunization with a rotavirus VP6 DNA vaccine encapsulated in poly(lactide-coglycolide) (PLG) microparticles. One dose of vaccine given to BALB/c mice elicited both rotavirus-specific serum antibodies and intestinal immunoglobulin A (IgA). After challenge at 12 weeks postimmunization with homologous rotavirus, fecal rotavirus antigen was significantly reduced compared with controls. Earlier and higher fecal rotavirus-specific IgA responses were noted during the peak period of viral shedding, suggesting that protection was due to specific mucosal immune responses. The results that we obtained with PLG-encapsulated rotavirus VP6 DNA are the first to demonstrate protection against an infectious agent elicited after oral administration of a DNA vaccine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621034      PMCID: PMC110376     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Intracellular neutralization of virus by immunoglobulin A antibodies.

Authors:  M B Mazanec; C S Kaetzel; M E Lamm; D Fletcher; J G Nedrud
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

2.  Oral delivery of micro-encapsulated DNA vaccines.

Authors:  D H Jones; J C Clegg; G H Farrar
Journal:  Dev Biol Stand       Date:  1998

3.  Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response.

Authors:  J H Eldridge; J A Meulbroek; J K Staas; T R Tice; R M Gilley
Journal:  Adv Exp Med Biol       Date:  1989       Impact factor: 2.622

4.  Biodegradable microspheres: vaccine delivery system for oral immunization.

Authors:  J H Eldridge; R M Gilley; J K Staas; Z Moldoveanu; J A Meulbroek; T R Tice
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

5.  Detection of rotavirus in human stools by using monoclonal antibody.

Authors:  G Cukor; D M Perron; R Hudson; N R Blacklow
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

6.  Development of an adult mouse model for studies on protection against rotavirus.

Authors:  R L Ward; M M McNeal; J F Sheridan
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

7.  Role of coproantibody in clinical protection of children during reinfection with rotavirus.

Authors:  B S Coulson; K Grimwood; I L Hudson; G L Barnes; R F Bishop
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

Review 8.  Development of candidate rotavirus vaccines.

Authors:  R F Bishop
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

9.  Fecal antibody responses to symptomatic and asymptomatic rotavirus infections.

Authors:  D O Matson; M L O'Ryan; I Herrera; L K Pickering; M K Estes
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

10.  DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.

Authors:  E F Fynan; R G Webster; D H Fuller; J R Haynes; J C Santoro; H L Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

View more
  41 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines.

Authors:  Petra Riedl; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Mol Med (Berl)       Date:  2003-12-02       Impact factor: 4.599

Review 3.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

4.  Gene expression in tilapia following oral delivery of chitosan-encapsulated plasmid DNA incorporated into fish feeds.

Authors:  Erwin A Ramos; Jenne Liza V Relucio; Celia Aurora T Torres-Villanueva
Journal:  Mar Biotechnol (NY)       Date:  2005-03-11       Impact factor: 3.619

Review 5.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

6.  Chitosan-zein nano-in-microparticles capable of mediating in vivo transgene expression following oral delivery.

Authors:  Eric Farris; Deborah M Brown; Amanda E Ramer-Tait; Angela K Pannier
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

7.  Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.

Authors:  Toshio Naito; Yutaro Kaneko; Danuta Kozbor
Journal:  J Gen Virol       Date:  2007-01       Impact factor: 3.891

8.  Molecular epidemiology of human group A rotavirus infections in the United Kingdom between 1995 and 1998.

Authors:  M Iturriza-Gómara; J Green; D W Brown; M Ramsay; U Desselberger; J J Gray
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

9.  Evolving importance of biologics and novel delivery systems in the face of microbial resistance.

Authors:  Terry L Bowersock
Journal:  AAPS PharmSci       Date:  2002

10.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.